

Open Peer Review on Qeios

Recombinant Human Papillomavirus Bivalent Vaccine

National Cancer Institute

Source

National Cancer Institute. <u>Recombinant Human Papillomavirus Bivalent Vaccine</u>. NCI Thesaurus. Code C48395.

A recombinant, bivalent, human papillomavirus (HPV) vaccine, containing virus-like particles for HPV types 16 and 18 linked to the adjuvant ASO4, with potential immunoprotective and antineoplastic properties. Upon administration, HPV 16/18 L1 virus-like particle/ASO4 vaccine may generate humoral and cellular immunity against HPV types-16 and -18 antigens, thereby preventing cervical infection upon exposure to HPV types 16 and 18. In addition, this agent may stimulate an antitumoral cellular immune response against cervical cancer associated with HPV infection.

Qeios ID: X981DO · https://doi.org/10.32388/X981DO